Pre-earnings brief
Reports
Tue, May 5, 2026
Est. EPS
$-0.17
Est. revenue
$54M
Implied move
±5.2%
EPS beat rate
75%
Day One Biopharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for patients with cancer. Operating in the health care sector, its work is crucial as it aims to address unmet medical needs in oncology, particularly for pediatric patients.
Last quarter
In the last quarter, Day One reported an EPS of $-1.04, significantly missing expectations. The stock reacted positively, gaining 2.74% the next day despite the disappointing earnings.
EPS beat streak
0Q
EPS beat rate
75%
Avg EPS surprise
-8.39%
Avg 1-day reaction
-1.23%
Analysts expect Day One to report a narrower loss this quarter, with revenue projected at $54 million. Investors will be keen to see if the company can meet or exceed these expectations.
Bull case
If Day One beats the EPS estimate and shows strong revenue growth, it could signal a turnaround in financial performance and boost investor confidence.
Bear case
Conversely, if the company fails to meet expectations again, it may raise concerns about its ability to execute on its business strategy, leading to a negative market reaction.
Key metrics to watch
EPS
$-0.17Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$54MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the EPS come in better than the consensus estimate of $-0.17?
A narrower loss could indicate improved operational efficiency and boost investor sentiment.
Q2
How does the company plan to achieve the projected revenue of $54 million?
Understanding the drivers behind revenue expectations will be crucial for assessing future growth potential.
Why consensus could be wrong
The consensus may underestimate Day One's potential for revenue growth, especially given recent positive surprises in prior quarters.
Supporting evidence
The company has a history of beating EPS estimates, with a 75% beat rate over the last eight quarters.
Options pricing suggests a larger move than historical averages, indicating that the market may be overly cautious.
Key risk
If revenue exceeds $60 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is debating whether Day One can turn around its financial performance after recent misses.
Bull confirmed if
An EPS of $-0.09 or better, along with revenue exceeding $60 million, would confirm a positive outlook.
Bear confirmed if
An EPS worse than $-0.28 could signal ongoing challenges and confirm the bear case.
What the market is pricing for the move.
Implied Move
±5.2%
Historical Avg
±2.7%
The options market is pricing in a significant move around the earnings report, suggesting heightened uncertainty or anticipation.
Options are pricing ±5.2% while DAWN has averaged ±2.7% over the last 8 prints — setup is pricing rich.
30d HV
2.5%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 12 of 30 (40%)
This setup has occurred 30 times across Health Care in the last 2 years. 12 of 30 faded and 18 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.6%, with a raw directional average of +2.2% (modestly positive historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Day One beats expectations, history suggests the stock could rise around 2.66%, confirming a positive trend.
In line / cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further clarity.
Miss
A miss could lead to a decline, with historical patterns indicating an average drop of around 0.29%.
The lines on the call that would change the story.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%